A biotech company is seeking 20 people who have been declared clinically dead for an attempt to reawaken parts of their central nervous systems.
Philadelphia-based Bioquark, Inc. has been granted ethical approval from an Institutional Review Board in the United States and India for a clinical trial at Anupam Hospital in India. Over six weeks, people on life support after traumatic brain injuries will receive stem cells, nerve stimulation and other treatments.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Certain amphibians and fish can regenerate and heal major chunks of their brains after extreme injuries. Bioquark’s goal is to bring these abilities to people, eventually reversing brain death. But that’s pretty futuristic at this point. For now, the team is hoping that they’ll see evidence of regeneration in the upper spinal cord, which dictates our breathing and heartbeat.
